
About LogicBio Therapeutics, Inc
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient’s genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a collaboration with Children’s Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421
LogicBio Therapeutics, Inc News and around…
Latest news about LogicBio Therapeutics, Inc (LOGC) common stock and company :
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 28.8% to $3.22 during Thursday's pre-market ...
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Tuesday, May 24, 2022.
Gainers Allogene Therapeutics (NASDAQ:ALLO) shares increased by 12.7% to $7.98 during Tuesday's pre-market session. ...
LogicBio Therapeutics (NASDAQ:LOGC) reported its Q1 earnings results on Monday, May 16, 2022 at 08:30 AM. Here's what investors need to ...
LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.
Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares surged 68.4% to close at $140.00 on Tuesday. Pfizer ...
Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 70.0% to $141.34 during Tuesday's regular session. ...
Gainers Biohaven Pharmaceutical Holding Company Ltd. (NASDAQ: BHVN) shares jumped 70.8% to $142.01. Pfizer Inc (NYSE: PFE) will ...
Gainers Vroom, Inc. (NASDAQ: VRM) shares rose 38% to $1.49 in pre-market trading after the company reported better-than-expected ...
Gainers Hemisphere Media Group, Inc(NASDAQ: HMTV) shares climbed 78.8% to close at $6.74 on Monday after the company ...
Gainers Blue Water Vaccines (NASDAQ:BWV) shares increased by 43.6% to $5.4 during Monday's regular session. Trading ...
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the ...
TheFDA has lifted the clinical holdonLogicBio Therapeutics Inc's(NASDAQ: LOGC) LB-001 Investigational New ...
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on LogicBioTherapeutics’ (NASDAQ: LOGC) ...
Gainers TherapeuticsMD (NASDAQ:TXMD) shares rose 4466.2% to $7.0 during Monday's pre-market session. The ...
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company's LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. In its letter, the FDA acknowledged
Gainers iRhythm Technologies (NASDAQ:IRTC) stock rose 21.6% to $143.58 during Friday's pre-market session. The ...
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product ...
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand beginning at 7:00 a.m. ET on March 30, 2022.
According to Benzinga Pro data, during Q4, LogicBio Therapeutics (NASDAQ:LOGC) posted sales of $2.03 million. Earnings were up 11.02%, ...
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET.
LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates.
Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came back up in the final session for a firm finish.
Biotech stocks managed to close the week endingFeb. 4 with gains. Stocks recovered along with the broader markets early in the ...
LogicBio Therapeutics, Inc (LOGC) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare